相关实验视频

Updated: Jun 5, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

基于YAP/TAZ抑制剂的药物递送系统用于选择性瘤积累和癌症组合疗法

Ziqian Zhang¹, Zhangyi Luo¹, Haozhe Huang¹

¹Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.

Biomacromolecules

|December 7, 2024

概括

研究人员开发了新型前期药物聚合物,以改善YAP/TAZ抑制剂尼胺酸 (NA) 的输送. 这种纳米组合疗法通过向瘤并抑制生长,有效地增强了乳腺癌治疗.

科学领域:

在瘤学瘤学.
材料科学材料科学材料科学
纳米技术纳米技术

背景情况:

是的相关蛋白 (YAP) 和具有PDZ结合动机 (TAZ) 的转录协活性剂是癌症发展和治疗耐药性的关键驱动因素.
药理上抑制YAP/TAZ是一种有前途的癌症治疗策略.
尼酸 (NA) 是一种YAP/TAZ抑制剂,由于体内半衰期较差,其临床实用性有限.

研究的目的:

开发改善的前药物策略来抑制YAP/TAZ.
为了创建自组装的纳米颗粒,以提高尼胺酸的输送.
为了研究乳腺癌治疗的纳米组合疗法.

主要方法:

合成了一系列基于尼胺酸的前药物聚合物.
研究了自组装纳米粒子的物理化学特性.
利用最佳的前药物聚合物作为受体氨酸激酶抑制剂 (RTKI) 的微粒纳米载体.

主要成果:

开发出能够自组装成纳米粒子的前药物聚合物,从而提高了尼胺酸的生物可用性.
在瘤中选择性积累的最佳前药纳米载体.
与RTKIs (例如,达沙替尼) 的联合治疗协同抑制了瘤生长.

结论:

前药物聚合物纳米粒子提供了一种可行的策略,以克服尼胺酸的局限性.
纳米组合疗法在临床前乳腺癌模型中表现出增强的疗效.
这种方法有可能改善癌症治疗策略.

更多相关视频

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drug Distribution: Tissue Binding

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...